Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today provided additional details on ...

CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that an abstract of the research results of the confirmatory ...

HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, ...

ATX-559, a first-in-class oral DHX9 inhibitor, is being evaluated in a Phase 1/2 study with a focuson advanced or metastatic ...

Flatiron Health today announced 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of ...

Media ReleaseCOPENHAGEN, Denmark; May 22, 2025 First presentation of results from Phase 1/2 clinical trial of investigational rinatabart sesutecan (Rina-S®) in patients with recurrent/advanced endomet ...

The challenge, open from May 7 to June 7, invites school and university students to design a poster that answers the question ...

Researchers are arguing over whether ‘disruptive’ or ‘novel’ science is waning – and how to remedy the problem.